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Treatment of acute renal failure In newborns by continuous arterlo—ve-
nous bemofiltration. The treatment of acute renal failure (ARF) in the
newborn with hemo- or peritoneal dialysis is technically difficult and
may even be contraindicated. As in the adult, continuous arterio—ve-
nous hemoflitration (CAVH) may be an alternative therapy. We used
CAVH in the treatment of four newborns with ARF of different
etiology. Two brachial, one femoral and one umbilical arteries were
cannulated as arterial access, while three jugular and one umbilical
veins were used as venous return. An Amicon 0.005 m2 Polysulphon
Hollow Fiber hemofilter was connected to the patient with shortened
pediatric hemodialysis lines. Total blood volume of the extracorporeal
circuit was 15 to 22 ml. Before starting the procedure, an initial bolus of
heparin was administered to the patient (100 i.u./kg body wt) and a
successive continuous heparin administration was provided during the
treatment at the rate of 5 to 7 i.u./kg/hr. Hyperalimentation and/or
buffer solutions were used as replacement fluids and were administered
according to the patient's fluid balance. Mean data in the four patients
are summarized as follows. The age of the patients ranged from two to
12 days, while the average body weight was about 3 kg. The ultrafil-
tration rate during the treatment averaged 0,9 mI/mm with a plasma flow
ranging from 9.8 to 19.6 mI/mm. The treatment duration varied from 30
to 86 hrs. The treatment was well tolerated (patients I and 2 recovered,
and patients 3 and 4 died due to complications unrelated to the
treatment). Arterial pressure remained stable during the procedure.
Metabolic acidosis, when present, was corrected by increasing the
amount of buffer administered. BUN was maintained below 60 mg/dl in
three patients. In one patient catabolism was severe and CAVil was
discontinued due to increasing levels of BUN. In conclusion, CAVH
appears to be a safe alternative treatment for newborns with ARF
and/or fluid and electrolyte imbalance. Severe catabolism may limit its
application.
When acute renal failure (ARF) occurs in newborns, it is
mainly due to renal hypoperfusion secondary to intra- or
post-operative hypotension or to perinatal asphyxia—hypoxic
shock like conditions [I]. We generally treat these patients
using peritoneal dialysis. In fact hemodialysis may be danger-
ous or difficult to carry out in very small patients.
However, when ARF follows an episode of abdominal sur-
gery, peritoneal dialysis may be precluded or contraindicated
and an alternative treatment is required. The same problem may
arise when severe cardiovascular instability or hypotension are
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present. In these conditions we propose the use of continuous
arterio—venous hemofiltration (CAVil). This technique does
indeed appear to be particularly useful to treat ARF, fluid
overload and electrolyte derangements associated with oliguria
in the newborn when hemo- or peritoneal dialysis are pre-
cluded.
CAVH is a simple method for blood purification and fluid
withdrawal originally described by Kramer in 1977 [21. A small
hemofilter is connected to an artery and a vein, and the simple
arterio—venous hydrostatic gradient moves the blood through
the circuit producing slow continuous ultrafiltration.
Plasma depuration during CAVH is mainly obtained by
convection since the ultrafiltrate composition is similar to that
of the plasma water. No blood pumps are used. Very low blood
flows and transmembrane pressures operate in this system.
In recent years, CAVH has been widely used in adults as an
alternative treatment for critically ill patients when hemo- or
peritoneal dialysis were precluded due to the patient's clinical
conditions or due to technical problems [31. The known advan-
tages of this treatment are its simplicity, its rapid and easy
application (there is no need for specialized equipment or stall),
and its good clinical tolerance [4].
The aim of this paper is to present the technical and clinical
results obtained in four newborns treated with continuous
arterio—venous hemofiltration and to point out some guidelines
useful to perform CAVH in such small patients. We also report
some in vitro experiments we performed in order to optimize
the hemofilter and circuit performances.
Methods
Four oligoanuric newborns (three males and one female)
were treated by CAVil for a period ranging from 30 to 84 hrs.
Table 1 shows the detailed population. Patients 1 and 2 had
severe hypotension during episodes of abdominal surgery
(bowel necrosis and duodenal stenosis) and developed ARF.
Patient 3 underwent cardiac surgery as a result of congenital
malformative cardiopathy (left ventricular hypoplasia), and
developed a severe cardiovascular instability and hypotension.
Patient 4 had a septic shock and consequently developed ARF.
Patients 3 and 4 needed ventilator support prior and during the
treatment. CAVH was carried out as described by Lauer et al
[3] with partial modifications due to the size of the patients.
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Table 1. Population
Patient 1 2 3 4
Name G.L. L.W. C.S. B.A.
Sex M M F M
Gestational Age, weeks 40 39 39 38
Age, days 4 2 2 12
Body weight, kg 2.8 3.2 3.3 3.4
Blood pressure, mmHg 75/45 65/40 50/30 80/50
Heart rate, b/mm 125 120 165 145
Ventilator Support No No Yes Yes
BUN, mg/dl 38 35 23 32
Plasma Na, mEqlliter 138 142 127 133
Plasma K, mEq/liter 3.8 4.2 3.5 4.4
Serum HCO3, mEq/liter 19 21 13 15.5
Hematocrit, % 44 48 45 42
Urine output, mI/hr 0.7 0.5 0.5 0.2
Diagnosis Post-operative ARF
(Intestinal necrosis)
Post-operative ARF
(Pyloric stenosis)
Renal Hypoperfusion
(left ventr, hypoplasia,
cardiac surg.)
Abruptio placentae.
Septic shock ARF
Blood access
Several types of vascular access were used. The goal was the
generation of an arterio—venous hydrostatic gradient sufficient
to move the blood through the circuit. In two patients we
cannulated the brachial artery alter surgical preparation, while
in one patient we used the femoral artery. The jugular vein was
utilized as venous access. In the last patient we used the
umbilical artery and umbilical vein (still open in newborns). In
all the cases we used very short cannulas (32 mm), size 18 or 20
gauge depending on the site of cannulation and on the patient's
arterial pressure. The use of umbilical vessels is quite sale and
easy in the neonate, however this type of access cannot be used
for long time and cannot be used at all in patients aging more
than four to five days. Special care has to be taken in order to
avoid possible complications such as air embolism or infec-
tions. On the other hand, the risks of peripheral artery cannula-
tion are high and are linked to the possible reduction of the
blood flow to the leg or to the arm with consequent ischemic
lesions or thrombosis of the vessel. For this reason an accurate
inspection of the arterial blood access is strongly recommended
throughout the treatment. In any case the local conditions and
the patient's clinical situations are the main points in the choice
of the vascular access.
Circuit
Shortened pediatric hemodialysis lines were used to connect
the hemofilter to the arterial and venous cannulas. The arterial
line had a port for heparin infusion, while another port for the
infusion of replacement solution was placed in the venous line.
The blood lines were maintained as short as possible in order to
avoid any pressure drop along the tubes. The total blood
volume of the extracorporeal circuit ranged from 13 to 22 ml.
On each occasion the procedure was started with the circuit full
of blood or saline solution to avoid hypotension. The choice
was made according to the patient's hematocrit; when hemato-
crit was under 40% the circuit was primed with citrated blood,
while in the other cases, the heparinized saline solution used for
the priming procedures was adequate to begin the
extracorporeal therapy. A Polysulphon Hollow Fiber Minifilter
(0.005 sq.m) (Amicon, Lexington, Massachusetts, USA) was
used as the hemofilter. The ultrafiltrate collecting system was
connected to the ultrafiltrate port. The column of ultrafiltrate
between the filter and the collecting bag was maintained as high
as possible in order to increase the transmembrane hydrostatic
gradient.
Heparin infusion
Before starting the procedure, the circuit and the filter were
washed with 2000 cc of heparinized saline solution (5000
U/liter). According to the coagulative status of the patient
thrombin time, whole blood clotting time, and platelet count,
we administered an initial bolus of heparin (100 U/kg). Contin-
uous heparin infusion was provided during the treatment by a
pump, at the rate of 5 to 7 U/kg/hr. Whole blood clotting time
was controlled every three hours.
The procedure to prepare the filter was extremely important
for the subsequent filter life during the treatment. The mem-
brane is a sponge—like tissue which operates best in conditions
of maximal hydration. The permeability and biocompatibility
are directly related to the water content of the membrane and
this fact explains the high amount of heparinized solution used
for preparing such a small filter. The starting bolus of heparin
represents a quite large dose, but the neonate rapidly metabo-
lizes the heparin administered and the coagulation parameters
come back to normal after less than one hour. On the other
hand this ensures the maximal anticoagulant effect during the
first minutes of the treatment when the contact blood/
membrane is critical. The amount of heparin given during the
continuing therapy is quite low if compared with the doses
utilized for the standard hemofilters for CAVH. The explana-
tion is in the different geometry of the blood flow inside the
minifilter's fiber which has a much larger inner diameter. This
characteristic allows the blood to go faster in the fibers, so
lower filtration fractions are achieved with a parallel reduction
of the protein/membrane interactions and secondary layer ag-
gregation.
Replacement fluid
The amount of replacement was adapted to the patient's fluid
balance requirements. Hemofiltration, biofiltration, ringer—lac-
tate or hyperalimentation (glucose or amino acid) solutions
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Table 2. Operational parameters of the system.
Patient 1 2 3 4
Blood flow,
mi/mm 28.0 3.1 25.2 2.4 15.5 4.2 22.0 3.3
Plasma flow,
mi/mitt 19.6 2.6 18.7 2.0 9.8 3.9 14.3 3.0
Ultrafiltration rate,
mi/mitt 1.1 0.2 1.0 0.1 0.8 0.3 0,7 0.2
Filtration fraction,
% 6.0 1.3 5.2 0.1 8.0 1.6 5.3 1.0
Treatment dura-
tion, hours 86 78 30 48
Initial body
weight, kg 2.8 3.2 3.3 3.4
Final body
weight, kg 2.8 3.4 3.0 3.3
Outcome Recovered
Rest. Diur.
Recovered
Rest. Diur.
Dead Shifted to
PD
were used depending on the acid—base, electrolyte and/or
metabolic derangements that needed to be corrected.
Treatment monitoring
Blood samples for hematocrit and total plasma protein mea-
surements were taken from the arterial and venous lines to
assess blood flow (Qb) and filtration fraction (FF) (Table 2).
Venous blood samples for the determination of BUN, electro-
lytes and acid—base status were taken every six hours. When
required, blood transfusions were provided (20 cc). For blood
chemistry an autoanalyzer and a Radiometer ABL 3 device
were used. Ultraffitration rate was measured every 30 minutes
and ultrafiltrate samples were collected to calculate sieving
coefficients for several solutes. Blood pressure and heart rate
were under continuous control. Nitrogen and caloric intake
were controlled to assess the urea kinetic parameters. Simpli-
fied Gotch formulas [5] were applied in order to study the urea
kinetics. In patient 1 arterial, venous, pre- and post-filter
pressures were studied with a water column manometric sys-
tem. Oncotic pressure (n) was calculated from the Pap-
penheimer nomogram [6].
All the patients were olygoanuric (urine output less than 10
ml124 hrs) at the beginning of the treatment. CAVH was
interrupted only after 6 to 12 hours of diuresis restoration.
In vitro experiments
Cannulas, circuit and minifilter operational parameters were
assessed by means of in vitro experiments (Fig. 1). In Figure
lA, blood flows allowed by the 18 and 20 gauge cannulas were
measured under several applied hydrostatic pressures. The
hydrostatic pressures were obtained by gravity, raising the bag
to different levels above the cannulas (1 cm = 0.74 mmHg). In
Figures B and C, blood was pumped at different flows through
the filter (10 to 200 mI/mm). Filter inlet pressure and relative
ultrafiltration rate were measured by water column manometry
and graduate cylinder timed collection. Filter outlet pressure
was also measured to assess the end—to—end pressure drop at
different blood flows. In Figure 1D, the ifiter performances were
finally tested by measuring the ultrafiltration production at
different applied transmembrane pressures (TMP). Qb was
maintained at a stable level of 100 mllmin.
All the experiments were carried out with thermostated 37'C
blood taken from voluntary donors. The hematocrit was
adjusted at 28% by the addition of plasma.
Results
In vitro experiments. Figure 1 summarizes the results ob-
tained from the in vitro experiments. Figure 1A shows the blood
flows obtained from the cannulas used at different hydrostatic
pressures. Note that for pressures between 40 and 70 mmHg
(values described in the newborn as the mean arterial pressure),
blood flows range from 20 to 65 mllmin according to the size of
the cannula. Figure lB depicts the behavior of filter inlet
pressure at various blood flows. The resistance of the filter was
very low and the inlet pressure began to rise only at blood flows
higher than 100 mI/mm. This observation is supported by the
graph displayed in Figure IC, where the ultrafiltration rate (Qt)
is plotted against blood flow. Qf appears to be little affected by
changes in Qb under 100 mI/mm. For Qb higher than 100
mllmin, Qf shows a progressive increase until it reaches a
plateau determined by the maximal ultrafiltration rate allowed
by the membrane surface area. It must be noted that blood
flows higher than 100 mllmin can be obtained only with a blood
pump. This behavior suggests that the cannulas used in our
patients were effective in achieving blood flows adequate to
perform CAVH. Further increase in the diameter of the cannula
may increase Qb up to 80 to 100 mllmin. In this range of blood
flows, the hydrostatic pressure is little affected by changes in
Qb and consequently only small variations in Qf are obtained.
On the contrary, the risks involved in the vessel's cannulation
with a bigger size catheter are significantly higher. Figure lD
shows the ultrafiltration rates obtained with the filter under
conditions of various transmembrane pressures (TMP). For
pressures between 20 and 70 mmHg, Qf ranges from 0.5 to 2
mi/mm, Since the resistance of the filter is so low, the sponta-
neous hydrostatic gradient generated by the blood flow achiev-
able in vivo is almost negligible. In these conditions, to obtain
an ultrafiltration rate of about 1 mI/mm (required to maintain the
efficiency of the treatment), an additional pressure must be
applied. The column of ultrafiltrate between the filter and the
collecting bag exerts a negative pressure on the other side of the
membrane according to the equation: I cm H2O = 0.74 mmHg.
Therefore an ultrafiltrate line 60 cm long may add an extra
gradient of about 40 mmHg. Figure 2 depicts a typical profile of
the pressures operating in the circuit. The hydrostatic pressure
in the filter is slightly higher than the opposite oncotic force (r)
generated by plasma proteins. As the blood moves along the
filter, water is removed by ultrafiltration and plasma protein
concentration increases with a parallel increase in oncotic
pressure. Under these conditions, the negative pressure exerted
by the ultrafiltrate column becomes critical in the generation of
an adequate transmembrane pressure (Appendix).
The operational characteristics of this pediatric filter are a
little different from standard filters for CAVH. The main
difference is the extremely low resistance to blood flow and the
low Qf achievable per unit surface area. Finally, ultrafiltration
rate is not directly correlated with the blood flow in the filter,
and filtration fraction (FF) decreases progressively with the
increase in blood flow. This observation suggests that the
system does not operate at filtration pressure equilibrium. In
other words, the oncotic pressure in the filter never reaches
Mean arterial pressure, mmHg
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Fig. 2. Typical pressure profile along the CAVH circuit. The negative
pressure exerted by the ultrafiltrate column is critical in the generation
of the total transmembrane gradient. Symbols are: l'3, hydrostatic
pressure; , filtrate negative pressure.
values so high as to arrest ultrafiltration and this, of course, is
linked to the low ultrafiltration of the blood passing through the
filter.
Clinical results
Table 2 reports the data concerning the duration of the
treatment in each patient, the operational parameters of the
system and the outcome. The blood flow in our patients ranged
from 15 to 28 mllmin with a relative plasma flow ranging from
9.8 to 19.6 mI/mm. The ultrafiltration rate averaged 0.9 mllmin
and the ifitration fraction varied from 5 to 8%. The daily
production of ultrafiltrate (1384 230 ml) was generally re-
placed cc/cc by infusion of hyperalimentation or alkaline solu-
tions in order to maintain the desired body weight and to
achieve a good metabolic balance.
In all the patients the treatment was well tolerated and no
complications related to the technique occurred. Figure 3 summa-
rizes the behavior of some clinical parameters studied in each
patient. Figure 3A depicts the stability of the mean arterial
pressure during the treatment. It must be noted that even in
patient 3, who presented a severe hypotension due to the
malformative cardiopathy, CAVH did not worsen the blood
pressure levels. Cardiovascular stability was confirmed by the
absence of significant changes in the patients' heart rate (Fig. 3B).
Figure 3C shows the effective correction of the metabolic
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acidosis throughout the treatment. At steady—state, serum
bicarbonate was maintained at a stable level by the infusion of
buffered replacement solutions; the amount of buffer adminis-
tered was calculated on the basis of the bicarbonate losses in
the ultrafiltrate, the daily acid production and the scheduled
changes in body weight. Two patients required the administra-
tion of calcium supplements. Figure 3D reports the BUN levels
during the treatment, In patients 1 and 2, CAVH was able to
control the BUN levels under 60 mg/dl during the period of
anuria. An early application of parenteral hyperalimentation to
prevent cellular protein breakdown and catabolism was associ-
ated with the extracorporeal treatment. The clinical conditions
of the patients improved progressively and renal functions were
recovered in 58 and 72 hours respectively. In patient 3, BUN
levels were maintained in close to normal ranges, but despite a
good control of the renal insufficiency, the patient died owing to
cardiac arrest during an episode of ventricular arrythmia after
30 hours of treatment. Patient 4 developed a severe catabolic
state and BUN levels began to increase progressively. The
treatment did not appear to be sufficiently effective in removing
waste products. The amount of urea nitrogen (UN) removed by
ultrafiltration was not sufficient enough to control the blood
Table 3. CAVH urea kinetics (48 hr study)
Patient
#1
Patient
#4
Treatment time, mm 2880 2880
Ultrafiltration rate, mI/mm 1.1 0.7
Reinfusion rate, mI/mm 1.1 0.7
Urea generation rate, mg/mm 0.7 1.2
Total urea generation, mg/48 hr 2016 3456
Urea removal rate, mg/mm 0.5 0.5
Total urea removed, mg/48 hr 1440 1440
Changes in BUN concentration, mg/dI
concentrations. The explanation of the phenomenon may be found
in Table 3, where a comparison between urea kinetic parameters
in patients 1 and 4 is illustrated. A 48 hour urea nitrogen kinetic
study is displayed. The lower ultrafiltration rate in patient 4
affected the efficiency of the treatment by providing a reduced
clearance of the solutes. The UN removal rate was identical in the
two patients due to the different BUN concentrations. The daily
urea nitrogen production, however, was much higher in patient 4
due to the severe catabolism, and this explains the rise in BUN
concentration despite the treatment. This condition limited the
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Fig. 3. Clinical parameters recorded in the treated patients. A Mean arterial pressure; B Heart rate; C Serum bicarbonate; D BUN concentrations
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efficacy of the treatment which can operate only in conditions of
pure convective transport. The patient was shifted to peritoneal
dialysis in an attempt to improve solute removal by diffusion, but
he died 18 hours later. During the treatments there were no
technical problems or complications due to device or circuit
malfunction. The filter survived for the entire duration of the
treatment in all the cases and showed a complete absence of clots
when the treatment was discontinued.
Discussion
Continuous arterio—venous hemofiltration has been widely
used in the treatment of acute renal failure in adults with
satisfying results. CAVH is particularly indicated when medical
or technical problems complicate the management of ARF in the
critically ill patient. When ARF occurs in the newborn, the small
size of the patient may even increase the number of problems in
the substitute therapy. Technical advancements have led to the
possibility of treating newborn patients with hemodialysis using
small disposable lines and filters suitable for the patient's size. On
the other hand, peritoneal dialysis has also been performed
successfully in infants with ARF, permitting the control of the
metabolic parameters during the period of anuria.
However, hemodialysis or peritoneal dialysis may sometimes
be contraindicated due to clinical complications, or may not be
available or rapidly applicable due to the lack of equipment and
specialized staff. In these conditions an alternative treatment is
required. According to our results, CAVH can be used in the
treatment of ARF or water and electrolyte derangements in
newborns as an alternative to hemo or peritoneal dialysis [7—8].
To be successful, the treatment of ARF in infants requires not
only a wide experience in the management of renal patients, but
also the knowledge of the functional characteristics of the
kidney during the first days of life, and of the complex metab-
olism of the newborn. The newborn kidney has a cellular
deficiency and only 15 to 20% of the total adult cellular amount
is functioning at birth. Cortical nephrons are not functionally
mature and GFR, which ranges from 20 to 30 ml/min/l.73 sq.m
at birth, is mainly due to the contribution given by the juxta-
medullary nephrons. On the contrary, the metabolic rate is
higher than in adults if it is related to the body weight or surface
area, and therefore the kidney functional demand is also greater
in newborns than in adults. These situations in infants render
ARF an even more complicated syndrome. The fluid balance is
particularly problematic in a patient with a total body weight of
3 kg. The total body water can be calculated from 60 to 85% of
body weight according to the patient's hydration conditions. In
CAVH, the monitoring of the ultraffitration rate is easy and
continuous and the patient's fluid balance can easily be cor-
rected by varying the rate of the reinfusion. One of the main
problems is represented by the possible severe catabolism
occurring in patients with ARF and medical or surgical compli-
cations. CAVH produces a limited amount of ultrafiltrate with a
composition identical to the plasma water. Despite the advan-
tage of a continuous plasma volume refilling due to the isotonic
water removal, this characteristic results in the treatment not
being particularly efficient in the removal of solutes. This
drawback may limit the application of CAVH in patients with
severe catabolism. In fact, when a severe catabolic state is
present and the daily urea production exceeds 1.5 to 2 g/day,
the efficiency of the system must be increased by the use of
hyperalimentation and/or techniques designed to increase the
filtration rate. In order to increase the ultrafiltration rate, a
negative pressure created by a pump can be applied to the
ultrafiltration compartment with a consequent increase in filtra-
tion fraction. However, this fact may cause red cell damage and
bring about hemolysis or clotting. An early institution of
parenteral hyperalimentation may contribute to the reduction of
the rate of urea production and cellular protein breakdown.
Hyperalimentation can be carried out using glucose solutions,
mixed essential/nonessential amino acid solutions at the ratio of
2:1. The energy requirement ranges from 100 to 150 calories!
kg/day. Of course the hyperalimentation should be adapted to
the patient's fluid and electrolyte balances. When present,
metabolic acidosis can be corrected with sodium bicarbonate (2
mM/kg increase serum bicarbonate of 4 to 5 ruM/liter) in the
replacement solutions, however, the consequent sodium load
must be considered. Ringer-lactate solutions should be avoided
in the first days of life because of the lack of lactic dehydrog-
enase in the newborn. Finally, calcium and vitamin supple-
ments can be added to the replacement solution.
The results obtained in the four patients treated with CAVH
suggest that this treatment can be used for the ARF in infants. We
suggest CAVH treatment for the following clinical indications.
Fluid overload. Severe overhydration with pulmonary vascu-
lar congestion or edema may occur in the neonate not only due
to ARF, but also because of cardiac failure, excessive fluid
intake during operations and all the situations refractory to
diuretic therapy. Under those conditions it may be difficult to
control the body fluid balance. The use of CAVH may permit a
reduction in the fluid overload by maintaining a negative
balance of fluid during several hours of ultrafiltration. The slow
continuous ultrafiltration and the infusion of a lower amount of
substitution fluid produces a progressive decrease in body
weight. The removal of isotonic fluid allows for a continuous
plasma refilling due to the oncotic effect of proteins, and this
contributes to the cardiovascular stability observed during
CAVH. The slow ultraffitration achieved by CAVH produces a
significant decrease in ventricular afterload and a negative
sodium balance. Those effects may certainly contribute to the
observed decrease in peripheral vascular resistances with a
consequent increase in the cardiac index. Furthermore, the
cardiovascular stability achieved in CAVH may also contribute
to the rapid restoration of a normal renal blood perfusion.
Electrolyte and Acid-Base derangements. The manipulation
of the extracellular fluid made possible by CAVH permits the
treatment of several electrolyte derangements. Hypo—hyperna-
tremia, hypecalcemia, hyperkalemia, etc., can be managed by
changing the composition of the replacement solution. The
speed of correction depends on the rate of ultrafiltration and on
the rate of the fluid turnover. One mL/min, i.e., 1440 m1124 hr
represents about five times the circulating volume of a neonate
weighing 3 kg. This relatively high turnover of fluid can also be
usefully applied to vary the absolute amount of some electro-
lytes in the body. This fact is particularly useful in the treatment
of the edematogenous syndromes associated with hyponatremia
and increased total body sodium, where a negative sodium
balance is required.
As far as acid—base balance is concerned, different situations
should be considered. Bicarbonate loss during CAVH can
easily be measured in the ultrafiltrate. Due to Donnan's equi-
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librium, the sieving coefficient for bicarbonate is generally 1.1
to 1.2. When CAVH is applied without substitute fluid to reduce
the patient's fluid overload, the bicarbonate losses are compen-
sated by the reduction of the buffer distribution volume and the
serum concentration does not change. On the contrary, when
ultrafiltration is replaced cc/cc to maintain the body fluid
balance, the amount of bicarbonate lost in the ultrafiltrate must
be added to the replacement solution in order to maintain the
constant serum levels. Finally, when CAVH is utilized to
correct metabolic acidosis, the amount of buffer in the replace-
ment solution should exceed the amount lost in the ultrafiltrate.
Solute removal and blood purjfication. CAVH is not a
substitute for any of the treatments utilized up to today, but it
complements them as a possible new alternative therapy. Its
operational characteristics make CAVFI not particularly effi-
cient in removing waste products. This is mainly due to the
identical composition between ultrafiltrate and plasma water
and the low rate of ultrafiltration. Despite the low efficiency,
CAVH allowed us to treat four neonates who couldn't undergo
other treatments because of their critical clinical conditions. In
those cases and in other clinical conditions, such as multi-organ
failure, cardiovascular instability associated with ARF,
edemitigenous syndromes refractory to diuretic therapy and
cerebral edema, CAVH might even be proposed as a first choice
treatment because of its good clinical tolerance.
Conclusions
On the basis of our results we conclude that CAVH may
represent a suitable alternative treatment for acute renal failure
in the newborn. The treatment is simple, rapidly instituted and
can be carried out in those conditions in which hemo— or
peritoneal dialysis are contraindicated or precluded. The tech-
nique requires limited supplies and can easily be monitored
even by an unspecialized staff. The technique allows for a local
heparinization without systemic effects and permits the removal
of solutes and water from the body with a very good clinical
tolerance.
The need of an adequate blood access and a possible severe
catabolic state in the patient may limit the application of this
treatment. A study on new devices specially designed for
CAVil may improve the applicability and the efficiency of this
technique.
APPENDIX
I) Mean arterial pressure (PA):
= Syst. Press. + 2 Diast. Press,
3
2) Mean hydrostatic pressure (P):
— — Pi + Po
2
where: Pi and Po are the hydrostatic pressures measured
manometrically at the inlet(i) and outlet(o) of the
filter,
Pi was also calculated as PA —
wherezP= 8r.Qb
3) Ultrafiltrate pressure (Pt):
Calculated from the height of the column of ultrafil-
trate according to the formula: 1 cm H2O = 0.74
mmHg
4) Mean oncotic pressure (ir):
— 7+1TO
2
where: in and mo are the oncotic forces calculated at the
inlet and outlet of the filter from Landis and Pap-
penheimer nomogram
5) Ultrafiltration rate (Qf):
Hourly volumetric collection
6) Blood flow (Qb):
Qb= QfHtoHto — Hti
where: Hti and Hto are the hematocrit at the inlet and outlet
7) Plasma flow (Qp):
Op = Qb — Red Cell Mass where: Red Cell Mass = 1 —
8) Filtration fraction (FF):
FF = 1 — Prot.i
Qp Prot.o
where: Prot.i and Prot.o are the total plasma protein con-
centrations at the inlet and outlet of the filter.
9) Transmembrane pressure (TMP):
TMP = Pi + Po + P1 — +
2 2
or more exactly:
out out
TMP = 5 Pdl + Pf 5l)dl
10) Ultrafiltration rate (Qfl:
Qf = K TMP
where: K = coefficient of membrane permeability
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